After a couple of years in the doldrums with a bunch of negative phase 3 readouts, I thought this was a good opportunity to sit back and reflect on the next tranche of targets and see what we can learn about them.

The answers were quite surprising when you look at the group as a whole because not everything is about the PD(L)1 – CTLA4 axis, thank goodness.

In the latest preview we explore five different categories and highlight mostly early and novel developments coming along from early stage biotech companies, which may be of interest to our eager readers..

To continue reading our latest discussion on oncology new product development plus expert commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by